Avere Therapeutics to merge with NextCure Inc.
RTW Biotech Opportunities said private portfolio company Avere Therapeutics will go public via an all-stock reverse merger with NextCure Inc., expected by year-end. Avere plans $320 million and $500 million private placements totaling $820 million. The combined company will trade on Nasdaq as Avere Therapeutics, Inc. under ticker AVRX, funding AVR-001 through psoriasis Phase 2b and Phase 3, and ulcerative colitis Phase 2b.
How this was made
The 30-second read
Why it matters
The disclosed $820M funding and specified clinical use of proceeds create a near-to-medium term catalyst map for the resulting Nasdaq-listed entity, while the all-stock merger structure introduces deal-close and execution risk.
Market read
Traders can monitor merger-close probability and financing close timing, plus the clinical milestone calendar that the $820M is intended to fund.
What to watch
Investors may focus on clinical execution risk for AVR-001 (psoriasis Phase 2b readout and Phase 3 initiation) and on whether the funding truly covers timelines through key enrollment and regulatory milestones.
Background
RTW Biotech Opportunities says private portfolio company Avere will go public via an all-stock reverse merger with public company NextCure, with two private placements totaling $820M.
Ticker impact
NextCure is the public-company merger partner in an all-stock deal with Avere, expected to close by year-end and result in a new Nasdaq-traded entity.
Near-term volatility likely around merger headlines and financing close timing; direction depends on deal terms and any regulatory/closing risk.
The article discloses a planned all-stock merger plus $820M private placements, which typically supports deal value expectations, but it does not provide valuation, exchange ratio, or closing conditions.
Market effects
Highlights continued capital formation via reverse mergers and large private placements in IL-23 inflammatory disease programs.
LSE-listed RTW Bio is the disclosed sponsor, but the tradable outcome is Nasdaq-listed AVRX, potentially shifting attention to US biotech reverse-merger structures.
Reinforces global investor appetite for late-stage preclinical-to-Phase 3 transition funding in immunology.
Counterpoint
The headline value may be overstated because the article provides no valuation, exchange ratio, or detailed closing conditions, so deal risk could cap upside.
Key entities
- companyAvere Therapeutics
Private IL-23 oral-therapy developer planning to advance AVR-001 through psoriasis Phase 2b readout and Phase 3 initiation, plus ulcerative colitis Phase 2b initiation.
- companyNextCure Inc.
Public merger partner in an all-stock transaction with Avere, expected to close by year-end.
- companyRTW Biotech Opportunities Ltd
LSE-listed investment company that participates in the private placements and has executed multiple reverse mergers in 2026.
